Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Traws Pharma (TRAW) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Traws Pharma (TRAW) over the last 14 years, with Q2 2025 value amounting to 45.7%.

  • Traws Pharma's EBITDA Margin rose 2163543000.0% to 45.7% in Q2 2025 from the same period last year, while for Sep 2025 it was 554.64%, marking a year-over-year increase of 620816500.0%. This contributed to the annual value of 62997.35% for FY2024, which is 540159300.0% down from last year.
  • Per Traws Pharma's latest filing, its EBITDA Margin stood at 45.7% for Q2 2025, which was up 2163543000.0% from 9128.07% recorded in Q1 2025.
  • Traws Pharma's 5-year EBITDA Margin high stood at 45.7% for Q2 2025, and its period low was 216400.0% during Q2 2024.
  • For the 5-year period, Traws Pharma's EBITDA Margin averaged around 19952.94%, with its median value being 8538.6% (2021).
  • Its EBITDA Margin has fluctuated over the past 5 years, first plummeted by 2000000000bps in 2024, then skyrocketed by 2000000000bps in 2025.
  • Traws Pharma's EBITDA Margin (Quarter) stood at 6719.64% in 2021, then plummeted by -52bps to 10239.29% in 2022, then rose by 22bps to 7967.86% in 2023, then decreased by -18bps to 9425.0% in 2024, then surged by 100bps to 45.7% in 2025.
  • Its EBITDA Margin stands at 45.7% for Q2 2025, versus 9128.07% for Q1 2025 and 9425.0% for Q4 2024.